The US Food and Drug Administration (FDA) has approved a new lipid-lowering combination tablet that includes atorvastatin, which went off patent in 2011, and ezetimibe
The combination, is approved for the treatment of elevated LDL-cholesterol levels in:
The combination, is approved for the treatment of elevated LDL-cholesterol levels in:
1- patients with primary or mixed hyperlipidemia as an adjunct to dietary changes,
2- as well as for reducing cholesterol levels in patients with homozygous familial hypercholesterolemia (FH)
Source